Ümit SAVAŞCI
(Gülhane Eğitim Araştırma Hastanesi,)
İSMAİL YAŞAR AVCI
(Gülhane Eğitim Araştırma Hastanesi,)
Yıl: 2016Cilt: 8Sayı: 3ISSN: 2148-273XSayfa Aralığı: 125 - 134Türkçe

301 5
Kan ve Kan Bileşenleri ile Bulaşan Enfeksiyon Etkenleri ve Nükleik Asit Amplifikasyon Test (NAT) Yönteminin Önemi
Kan ve kan¸bileşenleri ile bulaşan enfeksiyonlar, özellikle viral hepatit virüsleri ve insan immün yetmezlik virüsü¸ (HIV), dünyada uzun zamandan beri önemli bir halk sağlığı sorunu olmuştur. Kan ve kan bileşenleri, enfeksiyon etkenlerinin bulaşması için en kolay, en basit ve direkt bir yoldur. Bakteriyel, viral, parazitik ve fungal pek çok enfeksiyon etkeninin kan ve kan bileşenleri yoluyla bulaşabildiği bilinmektedir.
Fen > Tıp > Enfeksiyon Hastalıkları
Fen > Tıp > Mikrobiyoloji
DergiAraştırma MakalesiErişime Açık
  • 1. Avcı İY, Turhan V, Çınar E. Kan Nakli ile Bulaşan Enfeksiyon Hastalıkları. T Klin J Med Sci 2000;20:317- 24.
  • 2. Kahn R. Diseases transmitted by blood transfusion. Hempathol 1983;14:2412. http://dx.doi.org/10.1016/s0046-8177(83)80024-0
  • 3. Douglas DD, Taswel HF. The prevalence of HBVDNA a1 detected by polymerase chain reaction in HBsAg negative, anti-HBc positive blood donors. Transfusion 1991;31(Supplement):653.
  • 4. Trepo C. Des hepatitis non-A, non-B au virus de hepatit C. Gastroenterol Clin Biol 1990;14:51.
  • 5. Balık I, Onul M, Kandilci S, Tekeli E. Çeşitli gruplarda Hepatit C Virüs antikorlarının prevalansı. Türkiye Klinikleri Gastroenterol Hepatol Derg 1990;1:55.
  • 6. Patchen Dellinger EP, Anaya DA. Infectious and immunologic consequences of blood transfusion. Critical Care 2004;8(Suppl 2):S18-23. http://dx.doi.org/10.1186/cc2847
  • 7. Bihl F, Castelli D, Marincola F, Dodd RY, Brander C. Transfusion-transmitted infections. J Translational Medicine 2007;5:25. http://dx.doi.org/10.1186/1479-5876-5-25
  • 8. Kan ve Kan Ürünleri Yönetmeliği. 04.12.2008 tarih ve 27074 sayılı resmi gazete.
  • 9. De Vries RRP. Hemovigilance: A Quality Tool for the Blood Transfusion Chain. In De Vries RRP, Faber JC. Hemovigilance: An Effective Tool for Improving Transfusion Safety. 2012, John Wiley & Sons, p:5-11. http://dx.doi.org/10.1002/9781118338179.ch2
  • 10. Politis C. Testing, issing, and transport of blood components. In: De Vries RRP, Faber JC. Hemovigilance: An Effective Tool for Improving Transfusion Safety. 2012, John Wiley & Sons, p:113-25.
  • 11. Hoofnagle JH. Posttransfusion hepatitis B. Transfusion 1990;30(5):384-6. http://dx.doi.org/10.1046/j.1537-2995.1990.30590296367.x
  • 12. O'Brien SF, Fearon MA, Yi QL, Fan W, Scalia V, Muntz IR et al. Hepatitis B virus DNA positive, hepatitis B surface antigen negative blood donations intercepted by anti-hepatitis B core antigen testing: the Canadian Blood Services experience. Transfusion 2007;47(10):1809-15. http://dx.doi.org/10.1111/j.1537-2995.2007.01396.x
  • 13. Arraes LC, Ximenes R, Andrieu JM, Lu W, Barreto S,Pereira LMMB et al. The Biological Meaning of AntiHBc Pozitive Result in Blood Donors: Relation to HBV DNA and to Other Serological Markers. Rev Inst Med Trop S Paulo 2003;45(3):137-40. http://dx.doi.org/10.1590/S0036-46652003000300004
  • 14. Hennig H, Puchta I, Luhm J, Schlenke P, Goerg S, Kirchner H. Frequency and load of hepatitis B virus DNA in first-time blood donors with antibodies to hepatitis B core antigen. Blood 2000;100(7):2637-41. http://dx.doi.org/10.1182/blood-2002-03-0798
  • 15. Kleinman SH, Kuhns MC, Todd DS, Glynn SA, McNamara A, DiMarco A et al. Frequency of HBV DNA detection in US blood donors testing positive for the presence of anti-HBc: implications for transfusion transmission and donor screening. Transfusion 2003; 43(6):696-704. http://dx.doi.org/10.1046/j.1537-2995.2003.00391.x
  • 16. Almeida-Neto C, Strauss E, Sabino EC, Sucupira MCA, Chamone DAF. Significance of isolated hepatitis B core antibody in blood donors from Sao Paulo. Rev Inst Med Trop 2001;43(4):203-8. http://dx.doi.org/10.1590/S0036-46652001000400005
  • 17. Manzini P, Girotto M, Borsotti R, Giachino O, Guaschino R, Lanteri M et al. Italian blood donors with antiHBc and occult hepatitis B virus infection. Haematologica 2007;92(12):1664-70. http://dx.doi.org/10.3324/haematol.11224
  • 18. Chaudhuri V, Nanu A, Panda SK, Chand P. Evaluation of serologic screening of blood donors in India reveals a lack of correlation between anti-HBc titer and PCR-amplified HBV DNA. Transfusion 2003; 43(10):1442-8. http://dx.doi.org/10.1046/j.1537-2995.2003.00512.x
  • 19. Comanor L, Holland P. Hepatitis B virus blood screening: unfinished agendas. Vox Sang 2006;91(1):1-12. http://dx.doi.org/10.1111/j.1423-0410.2006.00773.x
  • 20. Liu CJ, Chen DS, Chen PJ. Epidemiology of HBV infection in Asian blood donors: emphasis on occult HBV infection and the role of NAT. J Clin Virol 2006; 36(Suppl 1):33-44. http://dx.doi.org/10.1016/S1386-6532(06)80007-7
  • 21. Pomper GJ, Wu Y, Snyder EL. Risks of transfusiontransmitted infections: 2003. Current Opinion in Hematology 2003;10(6):412-418. http://dx.doi.org/10.1097/00062752-200311000-00003
  • 22. Brojer E, Grabarczyk P, Liszewski G, Mikulska M, Allain JP, Letowska M et al. Characterization of HBV DNA+/HBsAg- blood donors in Poland identified by triplex NAT. Hepatology 2006;44(6):1666-74. http://dx.doi.org/10.1002/hep.21413
  • 23. Biswas R, Tabor E, Hsia CC, Wright DJ, Laycock ME, Fiebiget EW, et al. Comparative sensitivity of HBV NATs and HBsAg assays for detection of acute HBV infection. Transfusion 2003;43(6):788-98. http://dx.doi.org/10.1046/j.1537-2995.2003.00424.x
  • 24. Heyns ADP, Swanevelder JP, Lelie PN, Crookes RL, Busch MP. The impact of individual donation NAT screening on blood safety-the South African experience. ISBT Science Series 2006;1(1):203-8. http://dx.doi.org/10.1111/j.1751-2824.2006.00030.x
  • 25. Yugi H, Hino S, Satake M, Tadodoro K. Implementation of donor screening for infectious agents transmitted by blood by nucleic acid technology in Japan. Vox Sang 2005;89(4):265. http://dx.doi.org/10.1111/j.1423-0410.2005.00694.x
  • 26. Stolz M, Tinguely C, Graziani M, Fontana S, Gowland P, Buser A, et al. Efficacy of individual nucleic acid amplification testing in reducing the risk of transfusion-transmitted hepatitis B virus infection in Switzerland, a low-endemic region. Transfusion 2010; 50(12):2695-706. http://dx.doi.org/10.1111/j.1537-2995.2010.02732.x
  • 27. Meng Q, Wong C, Rangachari A, Tamatsukuri S, Sasaki M, Fiss E, et al. Automated multiplex assay system for simultaneous detection of Hepatitis B virus DNA, hepatitis C virus RNA, and human immunodeficiency virus Type 1 RNA. J Clinical Microbiology 2001;39(8):2937-45. http://dx.doi.org/10.1128/JCM.39.8.2937-2945.2001
  • 28. McCormick MK, Dockter J, Linnen JM, Kolk D, Wu Y, Giachetti C. Evaluation of a new molecular assay for detection of human immunodeficiency virus type 1 RNA, hepatitis C virus RNA, and hepatitis B virus DNA. J Clinical Virology 2006;36(3):166-76. http://dx.doi.org/10.1016/j.jcv.2005.12.003
  • 29. Nantachit N, Thaikruea L, Thongsawat S, Leetrakool N, Fongsatikul L, Sompan P, et al. Evaluation of a multiplex human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus nucleic acid testing assay to detect viremic blood donors in northern Thailand. Transfusion 2007;47(10):1803-8. http://dx.doi.org/10.1111/j.1537-2995.2007.01395.x
  • 30. Koppelman MH, Assal A, Chudy M, Torres P, De Villaescusa RG, Reesinket HW, et al. Multicenter performance evaluation of a transcription-mediated amplification assay for screening of human immunodeficiency virus-1 RNA, hepatitis C virus RNA, and hepatitis B virus DNA in blood donations. Transfusion 2005;45(8):1258-66.
  • 31. Gerlich WH, Bremer C, Saniewski M, Schüttler CG, Wend UC, Willems WR et al. Occult Hepatitis B Virus Infection: Detection and Significance. Dig Dis 2010;28(1):116-25. http://dx.doi.org/10.1159/000282074
  • 32. Yenen OŞ, Badur S. Prevalance of antibodies to Hepatitis C virus in blood donors and risk groups in Istanbul, Turkey. Eur J Clin Microbiol Infect Dis 1991;10(2):93-4. http://dx.doi.org/10.1007/BF01964417
  • 33. Köksal I, Biberoğlu K, Koç F. Hepatitis C Virus antibodies among risk groups in Turkey. Infection 1991; 19:228-9. http://dx.doi.org/10.1007/BF01644950
  • 34. The proceeding of the First International Symposium on Hepatitis C Virus. Blood transfusion and transmission of HCV. New Jersey9. Theilman L, Blazek M, Goeser K. False positive anti-HCV tests in rheumatoid arthritis. Lancet 1990;335:1346.
  • 35. Theilman L, Blazek M, Goeser K. False positive antiHCV tests in rheumatoid arthritis. Lancet 1990; 335:1346. http://dx.doi.org/10.1016/0140-6736(90)91229-4
  • 36. Laperche S, Le Marrec N, Girault A, Bouchardeau F, Servant-Delmas A, Maniez-Montreuil M, et al. Simultaneous Detection of Hepatitis C Virus (HCV) Core Antigen and Anti-HCV Antibodies Improves the Early Detection of HCV Infection. J Clin Microbiol 2005;43(8):3877-83. http://dx.doi.org/10.1128/JCM.43.8.3877-3883.2005
  • 37. Sauleda S, Esteban RI, Hernandez JM, et al. Evaluation of RNAand E2 antibodies in prospectively followed recipients of hepatitis G virus-infected blood. Transfusion 1999;39:633-8. http://dx.doi.org/10.1046/j.1537-2995.1999.39060633.x
  • 38. Lefrere JJ, Roudot-Thorowal F, Morand-Joubert L, et al. Prevalance of GB virus type C/hepatitis G virus RNA and anti-E2 in individuals at high or low risk for blood-borne or sexually-transmitted viruses. Evidence of sexual and parenteral transmission. Transfusion 1999;39:83-94. http://dx.doi.org/10.1046/j.1537-2995.1999.39199116899.x
  • 39. Ludlam CA, Haydon GH, Gillon J, Jarvis LM. Detection of a novel DNA virus (TTV) in blood donors and blood products. 1998;52(9123):191-5.
  • 40. Charlton M, Adjei P, Poterucha J, Zein N, Moore R, Therneau T, Krom R, et al. TT virus infection in North America blood donors, patients with fulminant hepatic failure, and cryptogenic cirrhosis. Hepatology 1998;28(3):839-42. http://dx.doi.org/10.1002/hep.510280335
  • 41. Erensoy S, Sayiner AA, Türkoğlu S, Canatan D, Akarca US, Sertöz R, Ozacar T, et al. TT virus infection and genotype distribution in blood donors and a group of patients from Turkey. Infection 2002;30(5):299- 302. http://dx.doi.org/10.1007/s15010-002-2185-z
  • 42. Robinson WS. Hepatitis B Virus and Hepatitis Delta Virus. In: Mandell GL, Douglas RG, Bennett JFC, eds. Principles and practice of infectious Disease. New York: Churchill Livingston lnc.1990:1204-31.
  • 43. Melief CJM, Goudsmith J. Transmission of lymphotropic retroviruses (HTLV-Iand LAL/HTLV-III) by blood transfusion and blood products. Vox Sang 1986; 50:1-11. http://dx.doi.org/10.1111/j.1423-0410.1986.tb04837.x
  • 44. Los APM, Archtertof L. Informing blood donors about AIDS and risk faktörs : Reactions to information provided in regional blood bank in Netherlands. AIDS 1989;3:349-441. http://dx.doi.org/10.1097/00002030-198907000-00006
  • 45. Busch MP. Laboratory diagnosis of HIV infection, Transfusion Med Rev 1988;2:250-63. http://dx.doi.org/10.1016/S0887-7963(88)70053-X
  • 46. Grundon AJ, Critchlay SE. Risk of HIV infection in recipients of tested blood from donors now anti HIV positive. Transfusion 1988;23:419-21. http://dx.doi.org/10.1046/j.1537-2995.1988.28588337327.x
  • 47. Genesea J, Jett BW, Popstein JS. What do Western Blot indeterminate paterns for human immunodeficiency virus mean in EIA negative blood donors, Lancet 1989;2:1023-5. http://dx.doi.org/10.1016/S0140-6736(89)91027-1
  • 48. Hellinger JA, Esseş M. Human immunodeficiency virus and other retroviruses. In: Gorbach SL, Bartlett JG, Blacklow NR, eds. Infectious Disease. Philadelphia: W.B:Saunders Company 1992:1797-825.
  • 49. Busch MP. Future trends in retrovirus testing. J Clin Immunoassays 1988;11:126-9.
  • 50. Bolton WY, Wylie BR, Kenrick KG. HTLV-1 and blood donors. Lancet 1989;1:1324-5. http://dx.doi.org/10.1016/S0140-6736(89)92713-X
  • 51. Nelson K, Donahue J, Ners P. Risk of transfusion transmitted HIV-1 and HTLV-I/II. Transfusion 1991;31 (Supplement):475.
  • 52. Larson CJ. Human T-Cell leukemia virus Type I (HTLV-1) and blood transfusion. Mayo Clin Proc 1988;63:869-85. http://dx.doi.org/10.1016/S0025-6196(12)62689-5
  • 53. Ho M, Dowling JN. Cytomegalovirus infection in transplant and cancer patients. New York: Mc GrawHill Book, 1980.
  • 54. Tabor E. Bacterial infections transmitted by blood. In:Infectious complications of blood transfusion. New York: Academic Press 1982;147-65.324.
  • 55. Günhan C. Ege bölgesinde Sitomegalovirus (CMV) infeksiyonunun epidemiyolojik durumu. K.Ü. Tıp Fak. Mec 1971;10:425.
  • 56. Mete Z, Yenen OŞ. Kan donörleri ve çocuklarda sitomegalovirus (CMV) IgM ve IgG antikor prevalansı. Infeksiyon Derg 1988;2:227.
  • 57. Barbara JAJ. Microbiology in Blood Transfusion. Bristol: John Wright and Sons, 1983.
  • 58. Lunel F, Agut H, Robert C. Is human herpes virus (HHV-6) infection associated with postransfusion hepatitis. Transfusion 1991;31:872. http://dx.doi.org/10.1046/j.1537-2995.1991.31992094679.x
  • 59. Luppi M, Toralli G. The new lymphotropic herpesviruses (HHV-6, HHV-7, HHV-8) and hepatitis C virus (HCV) in human lymphoproliferative diseases. Haematologica 1996;81(3):265-81.
  • 60. Mollison PL, Engelfriet CP, Contreras MC. Blood transfusion in clinical medicine: London; Oxford press 9th. Edition 1993:770.
  • 61. Akiba J, Umemura T, Alter HJ, Kojiro M, Tabor E. SEN virus: epidemiology and characteristics of a transfusion-transmitted virus. Transfusion 2005;45(7):
  • 62. Naoumov NV, Petrova EP, Thomas MG, and Williams R. Presence of a newly described human DNA virus (TTV) in patients with liver disease. Lancet 1998;352:195-7. http://dx.doi.org/10.1016/S0140-6736(98)04069-0
  • 63. Simmonds P, Davidson F, Lycett C, Prescott LE, MacDonald DM, et al. Detection of a novel DNA virus (TTV) in blood donors and blood products. Lancet 1998;352:191-5. http://dx.doi.org/10.1016/S0140-6736(98)03056-6
  • 64. Revised Recommendations for the Assessment of Donor Suitability and Blood Product Safety in Cases of Suspected Severe Acute Respiratory Syndrome (SARS) or Exposure to SARS. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research, 2003
  • 65. Schmidt M, Brixner V, Ruster B, Hourfar MK, Drosten K, Preiser W, Seifried E, et al. NAT screening of blood donors for severe acute respiratory syndrome coronavirus can potentially prevent transfusion associated transmissions. Transfusion 2004;44(4): 470-5. http://dx.doi.org/10.1111/j.1537-2995.2004.03269.x
  • 66. Guidance for Industry: Assessing Donor Suitability and Blood and Blood Product Safety in Cases of Known or Suspected West Nile Virus Infection. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research, 2005.
  • 67. Soendjojo A, Boedisanto M, Ilias MI. Syphilis d'enblee due to blood transfusion. Br J Vener Dis 1982;58:149-50.
  • 68. Barbara JAJ, Contreras M. Infectious complications ofblood trasfusion: bacteria and parasites. BMJ 1990; 300:386-9. http://dx.doi.org/10.1136/bmj.300.6721.386
  • 69. T.C. Sağlık Bakanlığı Ulusal Kan ve Kan Ürünleri Rehberi. Ankara: Çesa Basım Hizmetleri; 2011
  • 70. Aoki SK, Holland PV. Lyme Disease, Another transfusion risk? Transfusion 1989;29:460-5. http://dx.doi.org/10.1046/j.1537-2995.1989.29789369687.x
  • 71. Buchkolz DH, Aubuchon IP, Synder E. Proliferation of Yersinia enterocolitica in leukodepleted and nondepleted red cells. Transfusion 1991;31 (Supplement): 635.
  • 72. Wright DC, Selss IF, Einton KJ, Pierce RN. Fatal Yersinia enterocolities sepsis after blood transfusion Arch Pathol Lab Med 1985;109:1040-2.
  • 73. Heal JM, Jones ME, Forey J, et al. Fatal Salmonella septicemia after platelet transfusion, Transfusion 1987; 27:2-5. http://dx.doi.org/10.1046/j.1537-2995.1987.27187121466.x
  • 74. Fajardo LF. Malarial parasties within human platelets. JAMA 1974;229:1205-7. http://dx.doi.org/10.1001/jama.1974.03230470047024
  • 75. Neinstein RA. Transfusion associated infections. 2nd ed. Boston Toronto; Little, Brown Company 1986.
  • 76. Smith RP, Evans AT, Popusky M, Mill SL. Transfusion acquired babesiosis and failure of antibiotic treatment DAMA 1986;256:2726-7.
  • 77. Aubckon JP, Dzik WH. Survival of loa Loa in banked blood. Lancet 1983;19:647-8. http://dx.doi.org/10.1016/S0140-6736(83)91819-6
  • 78. Hawking F. The transference of microfilaria bancrofti into natural and unnatural hosts. Ann Trop Med 1940;34:121. http://dx.doi.org/10.1080/00034983.1940.11685091
  • 79. Klein R, Dumble LJ. Transmission of CreutzfeldtJakob Disease and blood transfusion. Lancet 1993;341: 768. http://dx.doi.org/10.1016/0140-6736(93)90549-V
  • 80. Guidance for Industry Use of Nucleic Acid Tests on Pooled and Individual Samples From Donors of Whole Blood and Blood Components, inculidind Source Plasma, to Reduce the risk of Transmission of Hepatitis B Virus, U.S. Department of Health and Human Services Food and Drug Administration Center For Biologics Evaluation and Research October 2012.
  • 81. Saygan MB. Türk Kızılayı'ında NAT uygulamaları ve NAT verilerinin paylaşılması. VIII. Ulusal Kan Merkezleri ve Transfüzyon Tıbbı Kongresi, Antalya, 14-18 Aralık, 2015; 117-129.

TÜBİTAK ULAKBİM Ulusal Akademik Ağ ve Bilgi Merkezi Cahit Arf Bilgi Merkezi © 2019 Tüm Hakları Saklıdır.